

### Hikma Pharmaceuticals PLC - EIP Vesting

LONDON, 4 March 2025: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("**Hikma**") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("**PDMR**") have received shares as a result of the vesting or exercise of their conditional share awards which were granted on 25 February 2022 under the 2014 Executive Incentive Plan ("**EIP**") Element C and on 17 March 2016 under the EIP Element B.

#### Notification and public disclosure of transactions by persons discharging managerial responsibilities

##### Said Darwazah

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Said Darwazah	
2	Reason for the notification		
a)	Position/status	Executive Chairman	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UXH4JI75	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	18,420
d)	Aggregated information	Price(s): nil Volume(s): 18,420	
e)	Date of the transaction	28 February 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	

##### Riad Mishlawi

1	Details of the person discharging managerial responsibilities / person closely associated		
---	---	--	--

a)	Name	Riad Mishlawi	
2	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UX-H4JI75	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element C and exercise of conditional awards under the EIP Element B. All Shares were retained.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	EIP Award, Element C: 18,691
		Nil	EIP Award, Element B: 19,890
d)	Aggregated information	Price(s): nil Volume(s): 38,581	
e)	Date of the transaction	28 February 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	

#### **Mazen Darwazah**

1	Details of the person discharging managerial responsibilities / person closely associated	
a)	Name	Mazen Darwazah
2	Reason for the notification	
a)	Position/status	Executive Vice Chairman
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UX-H4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083

b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	14,844
d)	Aggregated information	Price(s): nil Volume(s): 14,844	
e)	Date of the transaction	28 February 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	

#### **Khalid Nabils**

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Khalid Nabils	
2	Reason for the notification		
a)	Position/status	PDMR	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UX-H4JI75	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	17,003
d)	Aggregated information	Price(s): nil Volume(s): 17,003	
e)	Date of the transaction	28 February 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	

#### **Bassam Kanaan**

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>	
a)	Name	Bassam Kanaan

2	Reason for the notification		
a)	Position/status	PDMR	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UXH4JI75	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	16,472
d)	Aggregated information	Price(s): nil Volume(s): 16,472	
e)	Date of the transaction	28 February 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	

#### **Susan Ringdal**

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Susan Ringdal	
2	Reason for the notification		
a)	Position/status	PDMR	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UXH4JI75	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element C.	
	Price(s) and volume(s)	Price(s)	Volume(s)

c)		Nil	8,851
d)	Aggregated information	Price(s): nil Volume(s): 8,851	
e)	Date of the transaction	28 February 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares sold to cover tax following the vesting of conditional awards under the EIP Element C.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£21.71	4,173
d)	Aggregated information	Price(s): £21.71 Volume(s): 4,173 Total(s): £90,596.87	
e)	Date of the transaction	28 February 2025	
f)	Place of the transaction	London Stock Exchange (XLON)	

#### Hussein Arkhagha

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Hussein Arkhagha	
2	Reason for the notification		
a)	Position/status	PDMR	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	Hikma Pharmaceuticals PLC	
b)	LEI	549300BNS685UX-H4JI75	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083	
b)	Nature of the transaction	Shares acquired from the vesting of conditional awards under the EIP Element C. All Shares were retained.	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		Nil	8,675

d)	Aggregated information	Price(s): nil Volume(s): 8,675
e)	Date of the transaction	28 February 2025
f)	Place of the transaction	London Stock Exchange (XLON)

Helen Middlemist  
Group Company Secretary  
+44 (0)20 7399 2760

4 March 2025

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBBDXSBGDGUS